Our current data demonstrate that either shRNA‐mediated depletion of STAT3, or pharmacological inhibition of STAT3 with STAT3 inhibitor in prostate cancer cells, strikingly enhances NDV‐triggered expression and release of ICD markers, indicating that STAT3 participates with oncolytic NDV‐induced ICD in prostate cancer cells. Here, STAT3 is linked to prostate cancer.